0001144204-17-039116.txt : 20170731 0001144204-17-039116.hdr.sgml : 20170731 20170731060329 ACCESSION NUMBER: 0001144204-17-039116 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 27 CONFORMED PERIOD OF REPORT: 20170731 FILED AS OF DATE: 20170731 DATE AS OF CHANGE: 20170731 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Galmed Pharmaceuticals Ltd. CENTRAL INDEX KEY: 0001595353 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981147233 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36345 FILM NUMBER: 17991393 BUSINESS ADDRESS: STREET 1: 16 ZE'EV TYOMKIN ST. (4TH FL.) CITY: TEL AVIV STATE: L3 ZIP: 6578317 BUSINESS PHONE: 97236938448 MAIL ADDRESS: STREET 1: 16 ZE'EV TYOMKIN ST. (4TH FL.) CITY: TEL AVIV STATE: L3 ZIP: 6578317 6-K 1 v471329_6k.htm FORM 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of July 2017

001-36345

(Commission File Number)

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

16 Tiomkin St.

Tel Aviv 6578317, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover

Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(7): ____

This Form 6-K contains the quarterly report of Galmed Pharmaceuticals Ltd. (the “Company”), which includes the Company’s unaudited consolidated financial statements for the three and six months ended June 30, 2017, together with related information and certain other information. The Company is not subject to the requirements to file quarterly or certain other reports under Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company does not undertake to file or cause to be filed any such reports in the future, except to the extent required by law.

On July 31, 2017, the Company issued a press release announcing the filing of its financial results for the three and six months ended June 30, 2017 with the Securities and Exchange Commission. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This Form 6-K and the text under the heading “Financial Summary - Second Quarter 2017 vs. Second Quarter 2016” in Exhibit 99.1 is incorporated by reference into the Company’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on August 11, 2015 (Registration No. 333-206292) and its Registration Statement on Form F-3 filed with the Securities and Exchange Commission on March 31, 2015 (Registration No. 333-203133).

FINANCIAL INFORMATION

Financial Statements

GALMED PHARMACEUTICALS LTD.

Consolidated Balance Sheets

U.S. Dollars in thousands, except share data and per share data

	As of June 30, 2017			As of December 31, 2016
	Unaudited			Audited
Assets
Current assets
Cash and cash equivalents	$	1,747		$	3,097
Marketable securities		7,408			12,351
Other accounts receivable		266			284
Total current assets		9,421			15,732

Property and equipment, net		606			718

Total assets	$	10,027		$	16,450

Liabilities and stockholders' equity

Current liabilities
Trade payables	$	2,365		$	3,122
Other accounts payable		185			363
Short-term portion of deferred revenue		1,085			1,094
Total current liabilities		3,635			4,579

Long-term liabilities
Related parties		150			267
Long-term portion of deferred revenue		-			529
Total long-term liabilities		150			796

Stockholders' equity:
Ordinary shares par value NIS 0.01 per share; Authorized 50,000,000; Issued and outstanding: 12,219,186 shares as of June 30, 2017; 12,149,226 shares as of December 31, 2016		34			34
Additional paid-in capital		76,402			75,446
Accumulated other comprehensive loss		(20	)		(85	)
Accumulated deficit		(70,174	)		(64,320	)
Total stockholders' equity		6,242			11,075

Total liabilities and stockholders' equity	$	10,027		$	16,450

The accompanying notes are an integral part of the interim consolidated financial statements.

GALMED PHARMACEUTICALS LTD.

Consolidated Statements of Operations (Unaudited)

U.S. Dollars in thousands, except share data and per share data

	Three months ended June 30,					Six months ended June 30,
	2017			2016		2017			2016
Revenue	$	270		$	-	$	538		$	-

Research and development expenses		2,347			3,360		5,090			6,744

General and administrative expenses		624			861		1,413			1,580

Total operating expenses		2,701			4,221		5,965			8,324

Financial expenses (income), net		(9	)		89		(111	)		(30	)

Loss before income taxes		2,692			4,310		5,854			8,294

Taxes on Income		-			1		-			1

Net loss	$	2,692		$	4,311	$	5,854		$	8,295

Basic and diluted net loss per share	$	0.22		$	0.39	$	0.48		$	0.75

Weighted-average number of shares outstanding used in computing basic and diluted net loss per share		12,175,147			11,100,853		12,171,668			11,100,655

The accompanying notes are an integral part of the interim consolidated financial statements.

GALMED PHARMACEUTICALS LTD.

Consolidated Statements of Comprehensive Loss (Unaudited)

U.S. Dollars in thousands

	Three months ended June 30,						Six months ended June 30,
	2017			2016			2017			2016
Net loss	$	2,692		$	4,311		$	5,854		$	8,295

Other comprehensive loss (income):
Net unrealized loss (gain) on available for sale securities		(41	)		(56	)		(65	)		(102	)

Comprehensive loss	$	2,651		$	4,255		$	5,789		$	8,193

The accompanying notes are an integral part of the interim consolidated financial statements.

GALMED PHARMACEUTICALS LTD.

Consolidated Statements of Changes in Stockholders’ Equity (Unaudited)

U.S. Dollars in thousands, except share data and per share data

	Ordinary shares				Additional paid-in		Accumulated other Comprehensive			Accumulated
	Shares		Amount		capital		loss			Deficit			Total
Balance - December 31, 2016		12,149,226	$	34	$	75,446	$	(85	)	$	(64,320	)	$	11,075
Stock based compensation		-		-		709		-			-			709
Issuance of Ordinary Shares (*)		69,960		-		247		-			-			247
Unrealized gain from marketable securities		-		-		-		65			-			65
Net loss		-		-		-		-			(5,854	)		(5,854	)
Balance - June 30, 2017		12,219,186	$	34	$	76,402	$	(20	)	$	(70,174	)	$	6,242

(*) See note 3.3 and 3.4

The accompanying notes are an integral part of the interim consolidated financial statements.

GALMED PHARMACEUTICALS LTD.

Consolidated Statements of Cash Flows (Unaudited)

U.S. Dollars in thousands

	Six months ended June 30,
	2017			2016
Cash flow from operating activities

Net loss	$	(5,854	)	$	(8,295	)
Adjustments required to reconcile net loss to net cash used in operating activities
Depreciation and amortization		120			66
Stock-based compensation expense		709			1,063
Amortization of discount/premium on marketable securities		(207	)		35
Loss from Realization of marketable securities		115			138
Changes in operating assets and liabilities:
Decrease in other accounts receivable		18			43
Increase (decrease) in trade payables		(757	)		706
Increase (decrease) in other accounts payable		(178	)		106
Increase (decrease) in related party		(117	)		45
Decrease in deferred revenue		(538	)		-
Net cash used in operating activities		(6,689	)		(6,093	)

Cash flow from investing activities
Purchase of property and equipment		(8	)		(23	)
Investment in securities, available for sale		-			(1,212	)
Consideration of securities, available for sale		5,100			6,250
Net cash provided in (used in) investing activities		5,092			5,015

Cash flow from financing activities
Issuance of ordinary shares		247			11
Deferred issuance costs		-			(143	)
Net cash used in financing activities		247			(132	)

Increase (decrease) in cash and cash equivalents		(1,350	)		(1,210	)
Cash and cash equivalents at the beginning of the year		3,097			4,156
Cash and cash equivalents at the end of the period	$	1,747		$	2,946

Supplemental disclosure of cash flow information:
Cash received from interest	$	136			223

The accompanying notes are an integral part of the interim consolidated financial statements.

GALMED PHARMACEUTICALS LTD.

Notes to Consolidated Financial Statements

Note 1 - Basis of presentation

Galmed Pharmaceuticals Ltd. (the “Company”) is a clinical-stage biopharmaceutical company focused on the development of a novel, once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, and other liver diseases.

The Company in its current legal structure was incorporated in Israel on July 31, 2013 as a privately held company, and formally commenced operations on February 2, 2014. However, the Company’s business has been operating since 2000 under a different group of companies established in 2000 (the “Group”). On February 2, 2014, upon a pre-ruling from the Israeli Tax Authorities, the Company underwent a reorganization (the “Reorganization”), pursuant to which all of the business of its predecessor, Galmed Holdings Inc., including net assets and shares in its wholly-owned subsidiary, Galmed 2000, Inc. were transferred to the Company. Contemporaneously, the Company effected a 729-for-1 stock split.

These unaudited interim consolidated financial statements have been prepared as of June 30, 2017 and for the three and six month period then ended. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. These unaudited interim consolidated financial statements should be read in conjunction with the audited financial statements and the accompanying notes of the Company for the year ended December 31, 2016 that are included in the Company's Annual Report on Form 20-F, filed with the Securities and Exchange Commission on March 23, 2017 (the "Annual Report"). The results of operations presented are not necessarily indicative of the results to be expected for the year ending December 31, 2017.

Note 2 - Summary of significant accounting policies

The significant accounting policies that have been applied in the preparation of the unaudited consolidated interim financial statements are identical to those that were applied in preparation of the Company’s most recent annual financial statements in connection with its Annual Report on Form 20-F.

Note 3 - Stockholders' Equity

In January 2017, the Company granted options to purchase 130,000 ordinary shares of the Company, NIS 0.01 par value per share, to certain officers and employees. The options are exercisable at $3.84 per share, have a 10 year term and vest over a period of four years. The aggregate grant date fair value of such options is approximately $376 thousand.

In April 2017, the Company granted options to purchase 30,000 ordinary shares of the Company, NIS 0.01 par value per share, to two of its consultants. The options have an exercise price ranging between $4.75 and $4.87 per share, have a 10 year term and vest over a period of between one to four years. The aggregate grant date fair value of such options is approximately $99 thousand.

During June 2017, certain officers and former employees exercised 46,218 options into ordinary shares of the Company, NIS 0.01 par value per share, for total consideration of $247 thousand.

During the first half of 2017, a total of 23,742 restricted stock units were exercised into 23,742 ordinary shares of the Company, NIS 0.01 par value per share.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

All references to “we,” “us,” “our,” “the Company” and “our Company”, in this Form 6-K are to Galmed Pharmaceuticals Ltd. and its subsidiaries, unless the context otherwise requires. All references to “shares” or “ordinary shares” are to our ordinary shares, NIS 0.01 nominal par value per share. All references to “Israel” are to the State of Israel. “U.S. GAAP” means the generally accepted accounting principles of the United States. Unless otherwise stated, all of our financial information presented in this Form 6-K has been prepared in accordance with U.S. GAAP. Any discrepancies in any table between totals and sums of the amounts and percentages listed are due to rounding. Unless otherwise indicated, or the context otherwise requires, references in this Form 6-K to financial and operational data for a particular year refer to the fiscal year of our company ended December 31 of that year.

Our reporting currency and financial currency is the U.S. dollar. In this Form 6-K, “NIS” means New Israeli Shekel, and “$,” “US$” and “U.S. dollars” mean United States dollars.

Cautionary Note Regarding Forward-Looking Statements

This Form 6-K contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should,” “anticipate,” “could,” “might,” “seek,” “target,” “will,” “project,” “forecast,” “continue” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements may be included in, among other things, various filings made by us with the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the factors summarized below:

the timing and cost of our ongoing Phase IIB ARREST Study, and planned Phase III trials, for our product candidate, Aramchol^TM (hereinafter referred to as “Aramchol”) for the treatment of patients who are overweight or obese and have pre diabetes or type II diabetes mellitus (hereinafter OD patients) with Non-Alcoholic Steato-Hepatitis, or NASH, or whether Phase III trials will be conducted at all;

completion and receiving favorable results of these Phase IIB ARREST Study and Phase III trials for Aramchol;

regulatory action with respect to Aramchol by the U.S. Food and Drug Administration, or FDA, or the European Medicines Authority, or EMA, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling;

the commercial launch and future sales of Aramchol or any other future products or product candidates;

our ability to comply with all applicable post-market regulatory requirements for Aramchol in the countries in which we seek to market the product;

our ability to achieve favorable pricing for Aramchol;

our expectations regarding the commercial market for NASH in OD patients;

third-party payor reimbursement for Aramchol;

our estimates regarding anticipated capital requirements and our needs for additional financing;

market adoption of Aramchol by physicians and patients;

the timing, cost or other aspects of the commercial launch of Aramchol;

the development and approval of the use of Aramchol for additional indications or in combination therapy; and

our expectations regarding licensing, acquisitions and strategic operations.

We believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in our Annual Report on Form 20-F for the year ended December 31, 2016 filed with the SEC on March 23, 2017 in greater detail under the heading “Risk Factors” and elsewhere in the Annual Report and this Form 6-K. Given these uncertainties, you should not rely upon forward-looking statements as predictions of future events.

All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

Overview

We are a clinical-stage biopharmaceutical company focused on the development of Aramchol, a first in class, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. We are currently conducting the ARREST Study, a multicenter, randomized, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramchol in 248 subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. Top line data from the ARREST Study are expected to be available during the second quarter of 2018.

We also sponsor the ARRIVE Study, a proof-of-concept Phase IIa clinical trial designed to evaluate the safety and efficacy of Aramchol in up to 50 patients with HIV-associated NAFLD (Non-Alcoholic Fatty Liver Disease) and lipodystrophy. The ARRIVE Study is an investigator-initiated trial, conducted at the University of California San Diego by Professor Rohit Loomba. More information about the ARREST Study and the ARRIVE Study may be found on ClinicalTrials.gov identifiers: NCT02279524 and NCT02684591, respectively.

Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism. Aramchol’s ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating down regulation of the three key pathologies of NASH: steatosis, inflammation and fibrosis. The effect of Aramchol on fibrosis is mediated by down regulation of steatosis and directly on human collagen producing cells. We are investing efforts into better understanding the mechanisms by which Aramchol^TM down regulates steatosis and fibrosis. Additional animal models are being investigated with a variety of treatment regimens. The data, thus far, demonstrates dual mode of action of Aramchol on fibrosis via improvement of Fatty Acid oxidation as well a direct impact on stellate cells which are the collagen producing cells in the liver which results in reversing fibrosis. Aramchol has been granted by the FDA Fast Track designation status for the treatment of NASH.

Financial Overview

We have funded our operations primarily through the sale of equity and debt securities in private equity and debt financings in Israel to our affiliates (which has subsequently been converted in whole into common equity; no debt remains on our balance sheet), shareholders and third-party investors, and as of March 18, 2014, through the sale of our ordinary shares in our initial public offering. At June 30, 2017, we had current assets of $9.4 million, which consists of cash and cash equivalents of $1.7 million and short-term investment securities of $7.4 million. This compares with current assets of $15.7 million at December 31, 2016, which consists of cash and cash equivalents of $3.1 million and short-term investment securities of $12.4 million. Although we provide no assurance, we believe that such existing funds will be sufficient to continue our business and operations as currently conducted through the first half of 2018. However, we will continue to incur operating losses, which may be substantial over the next several years, and we may need to obtain additional funds to complete the ARREST Study, and further develop our research and development programs.

Recent Developments

During the second quarter of 2017, we announced the following developments:

In April, we presented at the International Liver Congress data that shows that Aramchol^TM has a potential direct effect on liver fibrosis.

On June 8, 2017, we announced the election of Dr. Carol L. Brosgart as a new member of our board of directors.

Since the end of the second quarter of 2017 (subsequent to the balance sheet date), we had the following developments:

The DMC for the ARREST study met in July to review the accumulated safety data. Following review of the data the DMC issued a positive recommendation for the continuation of the clinical trial with no changes to the protocol.

Dr. Tali Gorfine, our CMO, is currently on medical leave. Prof. Ran Oren, a member of our board of directors and our medical consultant (previously acted as the Company's CMO), together with Dr. Serena Rosner, M.D., who is working with Dr. Gorfine, have temporarily assumed Dr. Gorfine’s duties in her absence.

Revenues

On July 28, 2016, we entered into a license agreement, referred to herein as the Samil Agreement, with Samil Pharma. Co., Ltd. for the commercialization of Aramchol (with the option to manufacture) in the Republic of Korea. Under the terms of the Samil Agreement, we have received upfront payments of $2.1 million, and may be eligible to receive up to $6.0 million in additional payments for development and regulatory milestones for Aramchol in the licensed territories. For accounting purposes, the upfront payment has been recorded as deferred revenue. The deferred revenue is then amortized on a straight-line basis over the contractual period and milestone payments are recognized once earned.

Costs and Operating Expenses

Our current costs and operating expenses consist of two components: (i) research and development expenses; and (ii) general and administrative expenses.

Research and Development Expenses

Our research and development expenses consist primarily of outsourced development expenses, salaries and related personnel expenses and fees paid to external service providers, patent-related legal fees, costs of preclinical studies and clinical trials and drug and laboratory supplies. We charge all research and development expenses to operations as they are incurred. We expect our research and development expenses to remain our primary expenses in the near future as we continue to conduct clinical activities, as well as develop our products. Increases or decreases in research and development expenditures are attributable to the number or duration of the preclinical and clinical studies that we conduct.

We expect that a large percentage of our research and development expense in the future will be incurred in support of our current and future clinical and, to a lesser extent, preclinical development projects. Due to the inherently unpredictable nature of clinical and preclinical development processes, we are unable to estimate with any certainty the costs we will incur in the continued development of Aramchol for NASH and other indications in our pipeline for potential commercialization. Clinical development timelines, the probability of success for any given study, and development costs can differ materially from expectations. We expect to continue to conduct additional clinical trials for Aramchol, and to test Aramchol in preclinical studies for toxicology, safety and efficacy.

While we are currently focused on advancing our product development, our future research and development expenses will depend on the clinical success of Aramchol, as well as ongoing assessments of Aramchol’s commercial potential. As we obtain results from clinical trials, we may elect to discontinue or delay clinical trials for Aramchol in certain indications in order to focus our resources on more promising indications for Aramchol. Completion of clinical trials may take several years or more, but the length of time generally varies according to the type, complexity, novelty and intended use of Aramchol.

We expect our research and development expenses to increase in the future from current levels as we continue the advancement of our clinical product development and potentially in-license new product candidates. The lengthy process of completing clinical trials and seeking regulatory approval for Aramchol requires the expenditure of substantial resources. Any failure or delay in completing clinical trials, or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research and development expenses to increase and, in turn, have a material adverse effect on our operations. Because of the factors set forth above, we are not able to estimate with any certainty when we would recognize any net cash inflows from our projects.

General and Administrative Expenses

General and administrative expenses consist primarily of compensation for employees in executive and operational roles, including accounting, finance, legal and investor relations. Our other significant general and administrative expenses include non-cash stock-based compensation costs and facilities costs (including the rental expense for our offices in Tel Aviv, Israel), professional fees for outside accounting and legal services, travel costs, investors relations, insurance premiums and depreciation.

We expect our general and administrative expenses, such as accounting and legal fees, to increase as we grow and operate as a public company, and we expect an increase in our salary and benefits expense as a result of the additional management and operational personnel that we hired since our initial public offering to address the anticipated growth of our company, as well as performance-based salary increases and bonuses, if at all.

Financial Income, Net

Our financial income consists of interest income from marketable securities and short-term bank deposits. Our financial expense consists of bank fees.

Results of Operations

The table below provides our results of operations for the three and six months ended June 30, 2017 as compared to the three and six months ended June 30, 2016.

	Three months ended June 30,						Six months ended June 30,
	2017			2016			2017			2016
	(unaudited)			(unaudited)			(unaudited)			(unaudited)
	(In thousands, except per share data)

Revenue		270			-			538			-
Research and development expenses		2,347			3,360			5,090			6,744
General and administrative expenses		624			861			1,413			1,580
Total operating expenses		2,701			4,221			5,965			8,324
Financial expenses (income), net		(9	)		89			(111	)		(30	)
Taxes on income		-			1			-			1
Net loss		2,692			4,311			5,854			8,295
Other comprehensive income:		(41	)		(56	)		(65	)		(102	)
Comprehensive loss		2,651			4,255			5,789			8,193
Basic and diluted net loss per share	$	0.22		$	0.39		$	0.48		$	0.75

Revenue

Licensing revenue was approximately $270 thousand and approximately $538 thousand for the three and six months ended June 30, 2017, compared to no revenue for the three and six months ended June 30, 2016. The above mentioned revenue resulted from the amortization of the up-front payments under the license agreement with Samil Pharm.

Research and Development Expenses

Our research and development expenses amounted to approximately $2.3 million and approximately $5.1 million during the three and six months ended June 30, 2017, respectively, representing a decrease of approximately $1.1 million, or 32%, and approximately $1.6 million, or 24%, respectively, compared to approximately $3.4 million and approximately $6.7 million for the comparable period in 2016.

The decrease during the three months ended June 30, 2017 primarily resulted from a decrease of approximately $718 thousand in subcontractor expenses in connection with the ARREST Study, as well as a decrease of non-cash stock-based compensation expenses of approximately $376 thousand, as compared to such expenses for the comparable period in 2016.

The decrease during the six months ended June 30, 2017 primarily resulted from a decrease of approximately $594 thousand in subcontractor expenses in connection with the ARREST Study, as well as decreases of approximately $557 thousand in drug development related expenses and approximately $333 thousand in non-cash stock-based compensation expenses, as compared to such expenses for the comparable period in 2016.

General and Administrative Expenses

Our general and administrative expenses amounted to approximately $624 thousand and approximately $1.4 million during the three and six months ended June 30, 2017, respectively, representing a decrease of approximately $237 thousand, or 28%, and $167 thousand, or 11%, respectively, compared to approximately $861 thousand and approximately $1.6 million for the comparable period in 2016.

The decrease during the three months ended June 30, 2017 primarily resulted from a decrease of approximately $170 thousand in salaries and benefits, consisting of non-cash stock-based compensation and salaries paid to employees, as well as a decrease of approximately $80 thousand in professional fees , as compared to such expenses for the comparable period in 2016.

The decrease during the six months ended June 30, 2017 primarily resulted from a decrease of approximately $131 thousand in professional fees, as compared to such fees for the comparable period in 2016.

Operating Loss

As a result of the foregoing, for the three and six months ended June 30, 2017, our operating loss was approximately $2.7 million and approximately $6.0 million, respectively, representing a decrease of $1.5 million, or 36%, and $2.3 million, or 28%, respectively, as compared to our operating loss for the comparable prior year period. These decreases for the three and six months ended June 30, 2017 primarily resulted from a decrease in our research and development expenses as well as from our licensing revenue.

Financial (Income) Expense, Net

Our financial (income) expense amounted to approximately ($9) thousand and approximately ($111) thousand during the three and six months ended June 30, 2017, respectively, compared to $89 thousand and ($30) thousand for the comparable period in 2016.

The decrease during the three and six months ended June 30, 2017 primarily resulted from an increase in currency exchange rates expenses, as compared to such expenses for the comparable period in 2016.

Net Loss

As a result of the foregoing, for the three and six months ended June 30, 2017, our net loss was $2.7 million and $5.9 million, respectively, representing a decrease of $1.6 million, or 37%, and $2.4 million, or 29%, respectively, as compared to our net loss for the comparable prior year period.

Liquidity and Capital Resources

To date, we have funded our operations primarily through the sale of equity and debt securities in private equity offerings and debt financings in Israel to our affiliates (that has subsequently been converted in whole to common equity; no debt or debt-related securities remains on our balance sheet), shareholders and third-party investors, and as of March 18, 2014, through the sale of our ordinary shares in our initial public offering (approximately $39.9 million of net proceeds) and through our ATM Offering (approximately $4.5 million of net proceeds), and as well, through the upfront payment received from Samil (approximately $2.1 million). Furthermore, under our Sales Agreement, we may still raise up to approximately $11.5 million through the sale of additional ordinary shares in our ATM Offering, which was last used during September, 2016.

We have incurred substantial losses since our inception. As of June 30, 2017, we had an accumulated deficit of approximately $70.2 million and positive working capital (current assets less current liabilities) of approximately $5.8 million. We expect that operating losses will continue for the foreseeable future.

As of June 30, 2017, we had cash and cash equivalents of approximately $1.7 million and marketable securities of approximately $7.4 million invested in accordance with our investment policy, totaling approximately $9.1 million, as compared to approximately $3.1 million and approximately $12.4 million as of December 31, 2016, totaling approximately $15.5 million. The decrease is mainly attributable to our net loss of $5.9 million during the six months ended June 30, 2017.

We had negative cash flow from operating activities of approximately $6.7 million for the six months ended June 30, 2017, as compared to negative cash flow from operating activities of approximately $6.1 million for the six months ended June 30, 2016. The negative cash flow from operating activities for the six months ended June 30, 2017 is mainly attributable to our net loss of approximately $5.9 million, and as well, a decrease of approximately $1.5 million of trade payables, other accounts payables and upfront fee from license agreement; partially offset by non-cash stock based compensation expenses of approximately $709 thousand.

We had positive cash flow from investing activities of approximately $5.1 million for the six months ended June 30, 2017, as compared to positive cash flow from investing activities of approximately $5.0 million for the six months ended June 30, 2016. The positive cash flow from investing activities for both periods was primarily due to the consideration of marketable securities.

We had positive cash flow from financing activities of approximately $247 thousand for the six months ended June 30, 2017, as compared to negative cash flow from financing activities of approximately $132 thousand for the six months ended June 30, 2016. The positive cash flow from financing activities for the six months ended June 30, 2017 was due to proceeds from options exercise, while the negative cash flow from financing activities for the six months ended June 30, 2017 was due to issuance of ordinary shares net of issuance costs.

Although there can be no assurance, we believe that our existing cash resources will be sufficient to fund our projected cash requirements through the first half of 2018. Nevertheless, we will require significant additional financing in the future to fund our operations if and when we progress into Phase III trials of Aramchol and clinical trials for other indications, obtain regulatory approval of Aramchol and commercialize the drug. Our management may choose to raise such additional capital, which would be authorized by our board of directors, at their discretion.

Trend Information

We are a development stage company, and it is not possible for us to predict with any degree of accuracy the outcome of our research, development or commercialization efforts. As such, it is not possible for us to predict with any degree of accuracy any significant trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our net sales or revenues, income from continuing operations, profitability, liquidity or capital resources, or that would cause financial information to not necessarily be indicative of future operating results or financial condition. However, to the extent possible, certain trends, uncertainties, demands, commitments and events are in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations”.

Controls and Procedures

As a “foreign private issuer”, we are only required to conduct the evaluations required by Rules 13a-15(b) and 13a-15(d) of the Exchange Act as of the end of each fiscal year and therefore have elected not to provide disclosure regarding such evaluations at this time.

EXHIBIT INDEX

Exhibit No.		Description

99.1		Press Release, dated July 31, 2017
101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Galmed Pharmaceuticals Ltd.

Date: July 31, 2017	By:	/s/ Allen Baharaff
		Allen Baharaff
		President and Chief Executive Officer

EX-99.1 2 v471329_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Galmed Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update

- Conference Call and Webcast Today at 8:30 a.m. EDT / 5:30 a.m. PDT -

TEL AVIV, Israel, July 31, 2017 - Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, and other liver diseases, today reported financial results for the three and six months ended June 30, 2017. The Company will host a conference call and webcast today to discuss the financial results and to provide an update on current developments with respect to its clinical programs for Aramchol^TM.

Financial Summary - Second Quarter 2017 vs. Second Quarter 2016:

Net loss of $2.7 million, or $0.22 per share, for the three months ended June 30, 2017, compared to a net loss of $4.3 million, or $0.39 per share, for the three months ended June 30, 2016. This period’s net loss included $0.3 million of non-cash, stock-based compensation expense, versus $0.8 million of non-cash stock-based compensation expense incurred during the corresponding period in 2016.

The Company recognized $0.3 million of revenue for the three months ended June 30, 2017, compared to no revenue for the three months ended June 30, 2016. The revenue in this quarter relates to the amortization of the up-front payments under the license agreement with Samil Pharm.

Research and development (“R&D”) expenses amounted to approximately $2.3 million for the three months ended June 30, 2017, compared to approximately $3.4 million for the three months ended June 30, 2016. The decrease resulted primarily from a decrease in expenses in connection with the ARREST Study, as well as a decrease of non-cash stock-based compensation expenses.

General and administrative expenses amounted to approximately $0.6 million for the three months ended June 30, 2017, compared to approximately $0.9 million for the three months ended June 30, 2016. The decrease in general and administrative expenses for the three months ended June 30, 2017 resulted primarily from a decrease in professional fees, as well as a decrease in salaries and benefits expenses.

Financial income of $0.01 million for the three months ended June 30, 2017, compared to financial income of $0.1 million for the three months ended June 30, 2016. The decrease in financial income for the three months ended June 30, 2017 resulted primarily from changes in the foreign currency exchange rate.

Cash and cash equivalents and marketable securities totaled $9.1 million as of June 30, 2017, compared to $15.5 million at December 31, 2016. The decrease in cash resulted primarily from the costs of our ongoing clinical studies and operational activities. Galmed continues to believe that its cash balance will be sufficient to maintain its current operations through the first half of 2018, and allow the Company to complete the ARREST study as scheduled.

Conference Call & Webcast:

Monday, July 31, 2017, 8:30 am Eastern Time / 5:30 am Pacific Time

Participant Dial-In Numbers:

Toll-Free:	+1-888-287-5563
Toll/International:	+1-719-325-4878
Conference ID:	8068047
Webcast:	http://galmedpharma.investorroom.com/events

Replay, available until August 14, 2017

Replay Dial-In Numbers:

Toll-Free:	+1-844-512-2921
Toll/International:	+1-412-317-6671
Passcode:

About Aramchol^TM and Non-alcoholic Steatohepatitis (NASH)

Aramchol^TM (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism. Aramchol^TM’s ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating down regulation of the three key pathologies of NASH; steatosis, inflammation and fibrosis. The effect of Aramchol^TM on fibrosis is mediated by down regulation of steatosis and directly on human collagen producing cells. Aramchol^TM has been granted by the FDA Fast Track designation status for the treatment of NASH.

NASH is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally. It is the fastest growing cause of liver cancer and liver transplant in the U.S. due to the rise in obesity. NASH is the progressive form of non-alcoholic fatty liver disease that can lead to cardiovascular disease, cirrhosis and liver-related mortality.

About Galmed Pharmaceuticals Ltd.:

Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramchol^TM, a first in class, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. Galmed is currently conducting the ARREST Study, a multicenter, randomized, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramchol^TM in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. Galmed also sponsors the ARRIVE Study, a proof-of-concept Phase IIa clinical trial designed to evaluate the safety and efficacy of Aramchol in up to 50 patients with HIV-associated NAFLD and lipodystrophy. The ARRIVE Study is an investigator-initiated trial, conducted at the University of California San Diego by Professor Rohit Loomba. More information about the ARREST Study and the ARRIVE Study may be found on ClinicalTrials.gov identifiers: NCT02279524 and NCT02684591, respectively.

Forward-Looking Statements:

This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to Galmed’s objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that Galmed intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause Galmed’s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the timing and cost of Galmed’s ongoing Phase IIb ARREST Study, and planned Phase III trials for Aramchol^TM, or whether Phase III trials will be conducted at all; completion and receiving favorable results of these Phase IIb ARREST Study and Phase III trials for Aramchol^TM; regulatory action with respect to Aramchol^TM by the FDA or the EMA; the commercial launch and future sales of Aramchol^TM or any other future products or product candidates; Galmed’s ability to comply with all applicable post-market regulatory requirements for Aramchol^TM in the countries in which it seeks to market the product; Galmed’s ability to achieve favorable pricing for Aramchol^TM; Galmed’s expectations regarding the commercial market for NASH in patients who are overweight or obese and have pre diabetes or type II diabetes mellitus; third-party payor reimbursement for Aramchol^TM; Galmed’s estimates regarding anticipated capital requirements and Galmed’s needs for additional financing; market adoption of Aramchol^TM by physicians and patients; the timing, cost or other aspects of the commercial launch of Aramchol^TM; the development and approval of the use of Aramchol^TM for additional indications or in combination therapy; and Galmed’s expectations regarding licensing, acquisitions and strategic operations. More detailed information about the risks and uncertainties affecting Galmed is contained under the heading “Risk Factors” included in Galmed’s most recent Annual Report on Form 20-F filed with the SEC on March 23, 2017, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect Galmed’s current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Galmed Investor & Media Contact:

Guy Nehemya, VP Operations

Galmed Pharmaceuticals Ltd.

guy@galmedpharma.com

GALMED PHARMACEUTICALS LTD.

Consolidated Balance Sheets

U.S. Dollars in thousands, except share data and per share data

	As of June 30, 2017			As of December 31, 2016
	Unaudited			Audited
Assets
Current assets
Cash and cash equivalents	$	1,747		$	3,097
Marketable securities		7,408			12,351
Other accounts receivable		266			284
Total current assets		9,421			15,732

Property and equipment, net		606			718

Total assets	$	10,027		$	16,450

Liabilities and stockholders' equity

Current liabilities
Trade payables	$	2,365		$	3,122
Other accounts payable		185			363
Short-term portion of deferred revenue		1,085			1,094
Total current liabilities		3,635			4,579

Long-term liabilities
Related parties		150			267
Long-term portion of deferred revenue		-			529
Total long-term liabilities		150			796

Stockholders' equity:
Ordinary shares par value NIS 0.01 per share; Authorized 50,000,000; Issued and outstanding: 12,219,186 shares as of June 30, 2017; 12,149,226 shares as of December 31, 2016		34			34
Additional paid-in capital		76,402			75,446
Accumulated other comprehensive loss		(20	)		(85	)
Accumulated deficit		(70,174	)		(64,320	)
Total stockholders' equity		6,242			11,075

Total liabilities and stockholders' equity	$	10,027		$	16,450

GALMED PHARMACEUTICALS LTD.

Consolidated Statements of Operations (Unaudited)

U.S. Dollars in thousands, except share data and per share data

	Three months ended June 30,					Six months ended June 30,
	2017			2016		2017			2016
Revenue	$	270		$	-	$	538		$	-

Research and development expenses		2,347			3,360		5,090			6,744

General and administrative expenses		624			861		1,413			1,580

Total operating expenses		2,701			4,221		5,965			8,324

Financial expenses (income), net		(9	)		89		(111	)		(30	)

Loss before income taxes		2,692			4,310		5,854			8,294

Taxes on Income		-			1		-			1

Net loss	$	2,692		$	4,311	$	5,854		$	8,295

Basic and diluted net loss per share	$	0.22		$	0.39	$	0.48		$	0.75

Weighted-average number of shares outstanding used in computing basic and diluted net loss per share		12,175,147			11,100,853		12,171,668			11,100,655

GALMED PHARMACEUTICALS LTD.

Consolidated Statements of Cash Flows (Unaudited)

U.S. Dollars in thousands

	Six months ended June 30,
	2017			2016
Cash flow from operating activities

Net loss	$	(5,854	)	$	(8,295	)
Adjustments required to reconcile net loss to net cash used in operating activities
Depreciation and amortization		120			66
Stock-based compensation expense		709			1,063
Amortization of discount/premium on marketable securities		(207	)		35
Loss from Realization of marketable securities		115			138
Changes in operating assets and liabilities:
Decrease in other accounts receivable		18			43
Increase (decrease) in trade payables		(757	)		706
Increase (decrease) in other accounts payable		(178	)		106
Increase (decrease) in related party		(117	)		45
Decrease in deferred revenue		(538	)		-
Net cash used in operating activities		(6,689	)		(6,093	)

Cash flow from investing activities
Purchase of property and equipment		(8	)		(23	)
Investment in securities, available for sale		-			(1,212	)
Consideration of securities, available for sale		5,100			6,250
Net cash provided in (used in) investing activities		5,092			5,015

Cash flow from financing activities
Issuance of ordinary shares		247			11
Deferred issuance costs		-			(143	)
Net cash used in financing activities		247			(132	)

Increase (decrease) in cash and cash equivalents		(1,350	)		(1,210	)
Cash and cash equivalents at the beginning of the year		3,097			4,156
Cash and cash equivalents at the end of the period	$	1,747		$	2,946

Supplemental disclosure of cash flow information:
Cash received from interest	$	136			223

GRAPHIC 3 theader_ex99-1.jpg GRAPHIC begin 644 theader_ex99-1.jpg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tfooter_ex99-1.jpg GRAPHIC begin 644 tfooter_ex99-1.jpg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end EX-101.INS 5 glmd-20170630.xml XBRL INSTANCE DOCUMENT 0001595353 2016-01-01 2016-06-30 0001595353 2017-01-01 2017-06-30 0001595353 2016-04-01 2016-06-30 0001595353 2017-04-01 2017-06-30 0001595353 2017-06-30 0001595353 2016-12-31 0001595353 2015-12-31 0001595353 2016-06-30 0001595353 us-gaap:CommonStockMember 2016-12-31 0001595353 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001595353 us-gaap:RetainedEarningsMember 2016-12-31 0001595353 us-gaap:CommonStockMember 2017-01-01 2017-06-30 0001595353 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-06-30 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-06-30 0001595353 us-gaap:RetainedEarningsMember 2017-01-01 2017-06-30 0001595353 us-gaap:CommonStockMember 2017-06-30 0001595353 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-06-30 0001595353 us-gaap:RetainedEarningsMember 2017-06-30 0001595353 glmd:OfficersAndEmployeesMember 2017-01-01 2017-01-31 0001595353 glmd:OfficersAndEmployeesMember 2017-01-31 0001595353 glmd:ConsultantsMember 2017-04-01 2017-04-30 0001595353 glmd:ConsultantsMember 2017-04-30 0001595353 glmd:ConsultantsMember us-gaap:MinimumMember 2017-04-01 2017-04-30 0001595353 glmd:ConsultantsMember us-gaap:MaximumMember 2017-04-01 2017-04-30 0001595353 glmd:OfficersAndEmployeesMember 2017-01-01 2017-06-30 0001595353 glmd:OfficersAndEmployeesMember 2017-06-30 0001595353 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:ILS xbrli:shares 2013-07-31 2014-02-02 1747000 3097000 7408000 12351000 266000 284000 9421000 15732000 606000 718000 10027000 16450000 2365000 3122000 185000 363000 3635000 4579000 150000 267000 150000 -85000 -70174000 -64320000 6242000 11075000 10027000 16450000 796000 34000 76402000 75446000 -20000 34000 2347000 3360000 5090000 624000 861000 1413000 2701000 4221000 5965000 9000 -89000 111000 -2692000 -4310000 -5854000 0 1000 0 -2692000 -4311000 -5854000 0.39 0.48 0.22 12175147 11100853 12171668 6744000 1580000 8324000 30000 -8294000 1000 -8295000 0.75 11100655 41000 56000 65000 -2651000 -4255000 -5789000 102000 -8193000 34000 75446000 -85000 -64320000 12149226 247000 0 247000 0 0 69960 709000 0 709000 0 0 0 0 -5854000 34000 76402000 -20000 -70174000 12219186 0 65000 0 0 0 120000 66000 709000 1063000 -18000 -43000 -757000 706000 -178000 106000 -117000 45000 -6689000 -6093000 5092000 5015000 247000 11000 247000 -132000 -1350000 -1210000 4156000 2946000 -115000 35000 -138000 223000 136000 -207000 0 1212000 8000 23000 0 143000 6-K false 2017-06-30 2017 Q2 Galmed Pharmaceuticals Ltd. 0001595353 --12-31 Non-accelerated Filer GLMD 12219780 1085000 1094000 0 529000 270000 0 538000 0 0.01 0.01 50000000 50000000 12219186 12219186 12149226 12149226 -538000 0 5100000 6250000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -50.6pt; MARGIN: 0in 0in 0pt 50.6pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -50.6pt; MARGIN: 0in 0in 0pt 50.6pt"> <b><font style="FONT-SIZE: 10pt">Note 1 - Basis of presentation</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 50.6pt; TEXT-INDENT: -50.6pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 27.5pt" align="justify"><font style="FONT-SIZE: 10pt">Galmed Pharmaceuticals Ltd. (the “Company”) is a clinical-stage biopharmaceutical company focused on the development of a novel, once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, and other liver diseases.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 29.7pt; TEXT-INDENT: 27.5pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 27.5pt" align="justify"><font style="FONT-SIZE: 10pt">The Company in its current legal structure was incorporated in <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Israel</font> on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">July 31, 2013</font> as a privately held company, and formally commenced operations on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">February 2, 2014</font>. However, the Company’s business has been operating since 2000 under a different group of companies established in 2000 (the “Group”). On February 2, 2014, upon a pre-ruling from the Israeli Tax Authorities, the Company underwent a reorganization (the “Reorganization”), pursuant to which all of the business of its predecessor, Galmed Holdings Inc., including net assets and shares in its wholly-owned subsidiary, Galmed 2000, Inc. were transferred to the Company. Contemporaneously, the Company effected a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 729-for-1</font> stock split.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 27.5pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 27.5pt" align="justify"><font style="FONT-SIZE: 10pt">These unaudited interim consolidated financial statements have been prepared as of June 30, 2017 and for the three and six month period then ended. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. These unaudited interim consolidated financial statements should be read in conjunction with the audited financial statements and the accompanying notes of the Company for the year ended December 31, 2016 that are included in the Company's Annual Report on Form 20-F, filed with the Securities and Exchange Commission on March 23, 2017 (the "Annual Report"). The results of operations presented are not necessarily indicative of the results to be expected for the year ending December 31, 2017.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> Israel 729-for-1 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Note 2 - Summary of significant accounting policies</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 27.5pt" align="justify"><font style="FONT-SIZE: 10pt">The significant accounting policies that have been applied in the preparation of the unaudited consolidated interim financial statements are identical to those that were applied in preparation of the Company’s most recent annual financial statements in connection with its Annual Report on Form 20-F.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Note 3 - Stockholders' Equity</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">1.</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both;CLEAR: both"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">In January 2017, the Company granted options to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 130,000</font> ordinary shares of the Company, NIS <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.01</font> par value per share, to certain officers and employees. The options are exercisable at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.84</font> per share, have a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> year term and vest over a period of four years. The aggregate grant date fair value of such options is approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">376</font> thousand.</font> </div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">2.</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">In April 2017, the Company granted options to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30,000</font> ordinary shares of the Company, NIS <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.01</font> par value per share, to two of its consultants. The options have an exercise price ranging between $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.75</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.87</font> per share, have a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> year term and vest over a period of between one to four years. The aggregate grant date fair value of such options is approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">99</font> thousand. </font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">3.</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">During June 2017, certain officers and former employees exercised <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 46,218</font> options into ordinary shares of the Company, NIS <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.01</font> par value per share, for total consideration of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">247</font> thousand.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">4.</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">During the first half of 2017, a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 23,742</font> restricted stock units were exercised into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 23,742</font> ordinary shares of the Company, NIS <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.01</font> par value per share.</font></div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 130000 0.01 3.84 P4Y 376000 30000 0.01 4.75 4.87 P4Y 99000 46218 0.01 247000 23742 23742 0.01 P10Y P10Y P1Y See note 3.3 and 3.4 EX-101.SCH 6 glmd-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 106 - Statement - Consolidated Statements of Changes in Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 107 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Basis of presentation link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Summary of significant accounting policies link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Basis of presentation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 glmd-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 glmd-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 glmd-20170630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Legal Entity [Axis] Statement of Financial Position [Abstract] Statement [Table] Class of Stock [Axis] Class of Stock [Domain] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents at the beginning of the year Cash and cash equivalents at the end of the period Marketable Securities Marketable securities Accounts and Other Receivables, Net, Current Other accounts receivable Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Net book value Assets Total assets Liabilities and Equity [Abstract] Liabilities and stockholders' equity Liabilities, Current [Abstract] Current liabilities Accounts Payable, Trade, Current Trade payables Accounts Payable, Other, Current Other accounts payable Liabilities, Noncurrent [Abstract] Long-term liabilities Due to Related Parties, Noncurrent Related parties Deferred Revenue, Noncurrent Long-term portion of deferred revenue Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders' equity: Common Stock, Value, Issued Ordinary shares par value NIS 0.01 per share; Authorized 50,000,000; Issued and outstanding: 12,219,186 shares as of June 30, 2017; 12,149,226 shares as of December 31, 2016 Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total stockholders' equity Balance Balance Liabilities and Equity Total liabilities and stockholders' equity Common Stock, Par or Stated Value Per Share Ordinary shares, Par or Stated Value Per Share Common Stock, Shares Authorized Ordinary shares, Shares Authorized Common Stock, Shares, Issued Ordinary shares, Shares, Issued Common Stock, Shares, Outstanding Ordinary shares, Shares, Outstanding Income Statement [Abstract] Revenue, Net Revenue Research and Development Expense Research and development expenses Research and Development Expense General and Administrative Expense General and administrative expenses General and Administrative Expense Operating Expenses Total operating expenses Nonoperating Income (Expense) Financial expenses (income), net Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Loss before income taxes Loss before taxes on income, as reported in the consolidated statements of operations Income Tax Expense (Benefit) Taxes on Income Actual tax expense Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net loss Net loss Net loss Income (Loss) from Continuing Operations, Per Basic and Diluted Share Basic and diluted net loss per share Statement of Comprehensive Income [Abstract] Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive loss (income): Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Net unrealized loss (gain) on available for sale securities Unrealized gain from marketable securities Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Statement of Stockholders' Equity [Abstract] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Ordinary shares [Member] Additional Paid-in Capital [Member] Additional paid-in capital [Member] Accumulated Other Comprehensive Income (Loss) [Member] Accumulated other comprehensive loss [Member] Retained Earnings [Member] Accumulated deficit [Member] Shares, Outstanding Balance (in shares) Balance (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation and Exercise of Stock Options Stock based compensation Stock Issued During Period, Value, New Issues Issuance of Ordinary Shares Stock Issued During Period, Shares, New Issues Issuance of Ordinary Shares (in shares) Statement of Cash Flows [Abstract] Debt Conversion Description [Axis] Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flow from operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments required to reconcile net loss to net cash used in operating activities Depreciation, Depletion and Amortization Depreciation and amortization Share-based Compensation Stock-based compensation expense Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts and Other Receivables Decrease in other accounts receivable Increase (Decrease) in Accounts Payable, Trade Increase (decrease) in trade payables Increase (Decrease) in Other Accounts Payable Increase (decrease) in other accounts payable Increase (Decrease) in Due to Related Parties Increase (decrease) in related party Increase (Decrease) in Deferred Revenue Decrease in deferred revenue Amortization of Debt Discount (Premium) Amortization of discount/premium on marketable securities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flow from investing activities Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Payments to Acquire Available-for-sale Securities Investment in securities, available for sale Proceeds from Sale and Maturity of Available-for-sale Securities, Total Consideration of securities, available for sale Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flow from financing activities Proceeds from Issuance of Common Stock Issuance of ordinary shares Payments of Stock Issuance Costs Deferred issuance costs Cash and Cash Equivalents, Period Increase (Decrease) Increase (decrease) in cash and cash equivalents Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash used in financing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non cash activity: Proceeds from Interest Received Cash received from interest Marketable Securities, Realized Gain (Loss), Excluding Other than Temporary Impairments, Total Loss from Realization of marketable securities Debt Conversion, Name [Domain] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Basis of presentation [Table] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Entity Incorporation, Date of Incorporation Operations Commenced Date Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stockholders' Equity Note [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Short-term Debt, Type [Axis] Related Party [Axis] Short-term Debt, Type [Domain] Title of Individual [Axis] Related Party [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Number of share options, Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issuance of common stock upon stock option exercises (in shares) Number of share options, Exercised (in shares) Sale of Stock [Axis] Relationship to Entity [Domain] Award Type [Axis] Sale of Stock [Domain] Range [Axis] Equity Award [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average exercise price, Granted (in dollars per share) Shareholders' Equity and Share-based Payments [Text Block] Entity Incorporation, State Country Name Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash provided in (used in) investing activities Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Consultants [Member] Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Subsequent Event Type [Axis] Range [Domain] Minimum [Member] Maximum [Member] Restricted Stock Units (RSUs) [Member] Plan Name [Axis] Subsequent Event Type [Domain] Stockholders' Equity Note, Stock Split Deferred Revenue, Current Short-term portion of deferred revenue Long-term Debt, Excluding Current Maturities Total long-term liabilities Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted-average number of shares outstanding used in computing basic and diluted net loss per share Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Plan Name [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value Aggregate grant date fair value of options granted during the period. Basis of presentation [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Document Type Amendment Flag Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Liabilities, Current Total current liabilities Officers and Employees [Member] Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Document Information [Line Items] Entity [Domain] EX-101.PRE 10 glmd-20170630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.7.0.1

Document And Entity Information
6 Months Ended

Jun. 30, 2017

shares

Document Information [Line Items]

Entity Registrant Name Galmed Pharmaceuticals Ltd.

Entity Central Index Key 0001595353

Current Fiscal Year End Date --12-31

Entity Filer Category Non-accelerated Filer

Trading Symbol GLMD

Entity Common Stock, Shares Outstanding 12,219,780

Document Type 6-K

Amendment Flag false

Document Period End Date Jun. 30, 2017

Document Fiscal Period Focus Q2

Document Fiscal Year Focus 2017

Document And Entity Information	6 Months Ended
Jun. 30, 2017 shares
Document Information [Line Items]
Entity Registrant Name	Galmed Pharmaceuticals Ltd.
Entity Central Index Key	0001595353
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Trading Symbol	GLMD
Entity Common Stock, Shares Outstanding	12,219,780
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2017

XML 12 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 1,747	$ 3,097
Marketable securities	7,408	12,351
Other accounts receivable	266	284
Total current assets	9,421	15,732
Property and equipment, net	606	718
Total assets	10,027	16,450
Current liabilities
Trade payables	2,365	3,122
Other accounts payable	185	363
Short-term portion of deferred revenue	1,085	1,094
Total current liabilities	3,635	4,579
Long-term liabilities
Related parties	150	267
Long-term portion of deferred revenue	0	529
Total long-term liabilities	150	796
Stockholders' equity:
Ordinary shares par value NIS 0.01 per share; Authorized 50,000,000; Issued and outstanding: 12,219,186 shares as of June 30, 2017; 12,149,226 shares as of December 31, 2016	34	34
Additional paid-in capital	76,402	75,446
Accumulated other comprehensive loss	(20)	(85)
Accumulated deficit	(70,174)	(64,320)
Total stockholders' equity	6,242	11,075
Total liabilities and stockholders' equity	$ 10,027	$ 16,450

XML 13 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - ₪ / shares	Jun. 30, 2017	Dec. 31, 2016
Ordinary shares, Par or Stated Value Per Share	₪ 0.01	₪ 0.01
Ordinary shares, Shares Authorized	50,000,000	50,000,000
Ordinary shares, Shares, Issued	12,219,186	12,149,226
Ordinary shares, Shares, Outstanding	12,219,186	12,149,226

XML 14 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue	$ 270	$ 0	$ 538	$ 0
Research and development expenses	2,347	3,360	5,090	6,744
General and administrative expenses	624	861	1,413	1,580
Total operating expenses	2,701	4,221	5,965	8,324
Financial expenses (income), net	(9)	89	(111)	(30)
Loss before income taxes	2,692	4,310	5,854	8,294
Taxes on Income	0	1	0	1
Net loss	$ 2,692	$ 4,311	$ 5,854	$ 8,295
Basic and diluted net loss per share	$ 0.22	$ 0.39	$ 0.48	$ 0.75
Weighted-average number of shares outstanding used in computing basic and diluted net loss per share	12,175,147	11,100,853	12,171,668	11,100,655

XML 15 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net loss	$ 2,692	$ 4,311	$ 5,854	$ 8,295
Other comprehensive loss (income):
Net unrealized loss (gain) on available for sale securities	(41)	(56)	(65)	(102)
Comprehensive loss	$ 2,651	$ 4,255	$ 5,789	$ 8,193

XML 16 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Changes in Stockholders' Equity - 6 months ended Jun. 30, 2017 - USD ($)
$ in Thousands

Total

Ordinary shares [Member]

Additional paid-in capital [Member]

Accumulated other comprehensive loss [Member]

Accumulated deficit [Member]

Balance at Dec. 31, 2016

$ 11,075

$ 34

$ 75,446

$ (85)

$ (64,320)

Balance (in shares) at Dec. 31, 2016

12,149,226

Stock based compensation

709

$ 0

709

Issuance of Ordinary Shares

^[1]

247

$ 0

247

Issuance of Ordinary Shares (in shares)

^[1]

69,960

Unrealized gain from marketable securities

$ 0

Net loss

(5,854)

Balance at Jun. 30, 2017

$ 6,242

$ 34

$ 76,402

$ (20)

$ (70,174)

Balance (in shares) at Jun. 30, 2017

12,219,186

[1]	See note 3.3 and 3.4

XML 17 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flow from operating activities
Net loss	$ (5,854)	$ (8,295)
Adjustments required to reconcile net loss to net cash used in operating activities
Depreciation and amortization	120	66
Stock-based compensation expense	709	1,063
Amortization of discount/premium on marketable securities	(207)	35
Loss from Realization of marketable securities	115	138
Changes in operating assets and liabilities:
Decrease in other accounts receivable	18	43
Increase (decrease) in trade payables	(757)	706
Increase (decrease) in other accounts payable	(178)	106
Increase (decrease) in related party	(117)	45
Decrease in deferred revenue	(538)	0
Net cash used in operating activities	(6,689)	(6,093)
Cash flow from investing activities
Purchase of property and equipment	(8)	(23)
Investment in securities, available for sale	0	(1,212)
Consideration of securities, available for sale	5,100	6,250
Net cash provided in (used in) investing activities	5,092	5,015
Cash flow from financing activities
Issuance of ordinary shares	247	11
Deferred issuance costs	0	(143)
Net cash used in financing activities	247	(132)
Increase (decrease) in cash and cash equivalents	(1,350)	(1,210)
Cash and cash equivalents at the beginning of the year	3,097	4,156
Cash and cash equivalents at the end of the period	1,747	2,946
Supplemental disclosure of cash flow information:
Cash received from interest	$ 136	$ 223

XML 18 R8.htm IDEA: XBRL DOCUMENT

Basis of presentation

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note 1 - Basis of presentation

XML 19 R9.htm IDEA: XBRL DOCUMENT

Summary of significant accounting policies

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

Note 2 - Summary of significant accounting policies

XML 20 R10.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

6 Months Ended

Jun. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Shareholders' Equity and Share-based Payments [Text Block]

Note 3 - Stockholders' Equity

During June 2017, certain officers and former employees exercised 46,218 options into ordinary shares of the Company, NIS 0.01 par value per share, for total consideration of $247 thousand.

During the first half of 2017, a total of 23,742 restricted stock units were exercised into 23,742 ordinary shares of the Company, NIS 0.01 par value per share.

XML 21 R11.htm IDEA: XBRL DOCUMENT

Basis of presentation (Details Textual)	6 Months Ended
Basis of presentation (Details Textual)	Jun. 30, 2017
Basis of presentation [Line Items]
Entity Incorporation, Date of Incorporation	Jul. 31, 2013
Operations Commenced Date	Feb. 02, 2014
Entity Incorporation, State Country Name	Israel
Stockholders' Equity Note, Stock Split	729-for-1

XML 22 R12.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Textual) $ / shares in Units, $ in Thousands	1 Months Ended		6 Months Ended
	Apr. 30, 2017 USD ($) $ / shares shares	Jan. 31, 2017 USD ($) $ / shares shares	Jun. 30, 2017 USD ($) $ / shares shares	Jun. 30, 2017 ₪ / shares	Dec. 31, 2016 ₪ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Par or Stated Value Per Share \| ₪ / shares				₪ 0.01	₪ 0.01
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised \| shares			23,742
Officers and Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross \| shares		130,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period \| shares			46,218
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 3.84
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Common Stock, Par or Stated Value Per Share		$ 0.01	$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value \| $		$ 376
Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense) \| $			$ 247
Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross \| shares	30,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Common Stock, Par or Stated Value Per Share	$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value \| $	$ 99
Consultants [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 4.75
Consultants [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 4.87
Ordinary shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Par or Stated Value Per Share			$ 0.01
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures \| shares			23,742

EXCEL 23 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 24 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 25 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 27 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 29 85 1 true 9 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.galmedpharma.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - Consolidated Balance Sheets Sheet http://www.galmedpharma.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 103 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.galmedpharma.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 104 - Statement - Consolidated Statements of Operations Sheet http://www.galmedpharma.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 105 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.galmedpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 106 - Statement - Consolidated Statements of Changes in Stockholders' Equity Sheet http://www.galmedpharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity Consolidated Statements of Changes in Stockholders' Equity Statements 6 false false R7.htm 107 - Statement - Consolidated Statements of Cash Flows Sheet http://www.galmedpharma.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 108 - Disclosure - Basis of presentation Sheet http://www.galmedpharma.com/role/BasisOfPresentation Basis of presentation Notes 8 false false R9.htm 109 - Disclosure - Summary of significant accounting policies Sheet http://www.galmedpharma.com/role/SummaryOfSignificantAccountingPolicies Summary of significant accounting policies Notes 9 false false R10.htm 110 - Disclosure - Stockholders' Equity Sheet http://www.galmedpharma.com/role/StockholdersEquity Stockholders' Equity Notes 10 false false R11.htm 111 - Disclosure - Basis of presentation (Details Textual) Sheet http://www.galmedpharma.com/role/BasisOfPresentationDetailsTextual Basis of presentation (Details Textual) Details http://www.galmedpharma.com/role/BasisOfPresentation 11 false false R12.htm 112 - Disclosure - Stockholders' Equity (Details Textual) Sheet http://www.galmedpharma.com/role/StockholdersEquityDetailsTextual Stockholders' Equity (Details Textual) Details http://www.galmedpharma.com/role/StockholdersEquity 12 false false All Reports Book All Reports glmd-20170630.xml glmd-20170630.xsd glmd-20170630_cal.xml glmd-20170630_def.xml glmd-20170630_lab.xml glmd-20170630_pre.xml true true ZIP 29 0001144204-17-039116-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-17-039116-xbrl.zip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�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end